2021.10.05
I-Mab and ABL Bio jointly announced that data from the preclinical studies of TJ-CD4B/ABL111 and TJ-L14B/ABL503, will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place November 12 – 14, 2021.
2021.10.01
I-Mab today announced its participation in the following conferences in October.
2021.09.30
I-Mab today announced multiple clinical advancements of its anti-CD47 monoclonal antibody lemzoparlimab.
2021.09.28
I-Mab today announced that the Center for Drug Evaluation of China National Medical Products Administration has accepted the Company’s IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors in China.
2021.09.13
I-Mab will be added to the following FTSE ESG (Environmental, Social and Governance) Index Series, in addition to the FTSE Global Equity Index Series (“GEIS”).
2021.09.02
I-Mab today announced that the Company will be added to the following FTSE Global Equity Index Series, following FTSE’s most recent semi-annual review.
2021.08.31
I-Mab today announced financial results for the six months ended June 30, 2021, and provided key business updates.
2021.08.27
I-Mab today announced its participation in the following conferences in September.
2021.08.19
I-Mab today announced that its Board of Directors approved establishment of an ESG (Environmental, Social and Governance) Committee.
2021.08.17
Conference Call Scheduled at 7:00 a.m. ET (Mandarin) and 8:00 a.m. ET (English)